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Background: The use of adult stem cells is limited by the quality and quantity of host stem cells. It has been
demonstrated that Wharton’s jelly–derived mesenchymal stem cells (WJMSCs), a primitive stromal population, could
integrate into ischemic cardiac tissues and significantly improve heart function. In this randomized, controlled trial,
our aim was to assess the safety and efficacy of intracoronary WJMSCs in patients with ST-elevation acute myocardial
infarction (AMI).
Methods: In a multicenter trial, 116 patients with acute ST-elevation MI were randomly assigned to receive an
intracoronary infusion of WJMSCs or placebo into the infarct artery at five to seven days after successful reperfusion
therapy. The primary endpoint of safety: the incidence of adverse events (AEs) within 18 months, was monitored
and quantified. The endpoint of efficacy: the absolute changes in myocardial viability and perfusion of the infarcted
region from baseline to four months, global left ventricular ejection fraction (LVEF) from baseline to 18 months
were measured using F-18-fluorodeoxyglucose positron emission computed tomography (F-18-FDG-PET) and
99mTc-sestamibi single-photon emission computed tomography (99mTc-SPECT), and two-dimensional echocardiography,
respectively.
Results: During 18 months follow-up, AEs rates and laboratory tests including tumor, immune, and hematologic
indexes were not different between the two groups. The absolute increase in the myocardial viability (PET) and
perfusion within the infarcted territory (SPECT) was significantly greater in the WJMSC group [6.9 ± 0.6 % (95 %CI,
5.7 to 8.2)] and [7.1 ± 0.8 % (95 %CI, 5.4 to 8.8) than in the placebo group [3.3 ± 0.7 % (95 %CI, 1.8 to 4.7), P <0.0001]
and 3.9 ± 0.6(95 %CI, 2.8 to 5.0), P = 0.002] at four months. The absolute increase in the LVEF at 18 months in the
WJMSC group was significantly greater than that in the placebo group [7.8 ± 0.9 (6.0 to approximately 9.7) vs.
2.8 ± 1.2 (0.4 to approximately 5.1), P = 0.001]. Concomitantly, the absolute decreases in LV end-systolic volumes
and end-diastolic volumes at 18 months in the WJMSC group were significantly greater than those in the placebo
group (P = 0.0004, P = 0.004, respectively).
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Conclusions: Intracoronary infusion of WJMSCs is safe and effective in patients with AMI, providing clinically
relevant therapy within a favorable time window. This study encourages additional clinical trials to determine
whether WJMSCs may serve as a novel alternative to BMSCs for cardiac stem cell-based therapy.
Trial registration: Clinical Trials NCT01291329 (02/05/2011).
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Coronary artery disease (CAD) remains a major world-
wide cause of morbidity and mortality [1]. Despite re-
cent advances in treatments for acute myocardial infarc-
tion (AMI), the irreversible loss of cardiomyocytes after
an AMI leads to left ventricular (LV) remodeling and is-
chemic heart failure [1]. Regenerative cell therapies are
emerging as potential treatments for AMI [2]. Studies
have demonstrated the ability of transplanted mesenchy-
mal stem cells (MSCs) to engraft, differentiate into
cardiomyocyte-like and endothelial cells, and recruit en-
dogenous cardiac stem cells [3–6]. Clinical evidence has
shown that the intracoronary delivery of bone marrow
mononuclear cells (BMMCs) or bone marrow mesen-
chymal stem cells (BMSCs) can improve the ejection
fraction and reduce the infarct size [7–11]. However, the
viability and function of autologous adult stem cells de-
cline with age, especially in patients with MI [12, 13],
which significantly limits their viability for clinical trans-
plantation during the optimal window of opportunity to
prevent adverse left ventricular remodeling [12]. There-
fore, alternative sources of stem cells must be explored.
Wharton’s jelly-derived mesenchymal stem cells (WJMSCs),
a primitive stromal population [14, 15], have been iso-
lated from a continuum from the sub-amnion to the
perivascular region of the umbilical cord [14, 15]. Whar-
ton’s jelly of the umbilical cord originates from the ex-
traembryonic and/or the embryonic mesoderm at day
13 of embryonic development [15]. WJMSCs retain a
combination of most of their embryonic stem cell (ESC)
and MSC markers in primary culture and early passages,
thus retaining their multipotent stem cell characteristics
[15–17]. Using Affymetrix GeneChip microarray and
functional network analyses, we found for the first time
that WJMSCs, except for their expression of stemness mo-
lecular markers in common with human ESCs (hESCs),
exhibited a high expression of early cardiac transcription
factor genes and could be induced to differentiate into
cells expressing cardiac a-actin, troponin T and connexin-
43 in vitro [18]. Moreover, growing evidence has shown
that WJMSCs can be induced to differentiate into cardio-
myocytes and endothelial cells and to integrate into the
vasculature and ischemic cardiac tissue, as well as to im-
prove heart function significantly [19–22].In contrast to autologous adult stem cells, WJMSCs
display greater cardiovascular differentiation potential
[18–23], and more importantly, they are immune-privileged
and can be transplanted into unrelated recipients [24]. This
suggests the possibility of an allogeneic, “off-the-shelf” cell
product, which can be used during the optimal time-frame
for stem cell-based therapies after AMI, or even applied dir-
ectly following revascularization of the AMI [15–17, 24].
WJMSCs constitute an attractive alternative to autologous
MSCs for stem cell-based cardiac therapies [25].
Although our pilot clinical trial [26] and other clinical
studies [10] using allogeneic stem cells showed promising
results, there is no convincing evidence to date of the
therapeutic safety and efficacy of the use of WJMSCs in
humans. For this reason, this randomized, double-blind,
multicenter trial was performed to investigate the thera-




Patients with ST-elevation AMI were admitted to cardiology
centers in 11 hospitals in China between February 2011 and
January 2012. A total of 160 subjects were enrolled in the
trial. For inclusion in the study, patients had to satisfy the
following eligibility criteria: 18- to 80-years old; a first ST-
segment elevation MI; successful reperfusion with stent im-
plantation of the infarct-related artery within 12 hours after
the onset of symptoms; a substantial residual LV regional
wall-motion abnormality (three or more hypokinetic LV
segments observed on an echocardiograph after percutan-
eous coronary intervention, PCI); and creatine kinase (CK)-
MB levels over three-fold the upper limit of the reference
values. Exclusion criteria included previous Q-wave MI and
severe coexisting conditions, such as advanced renal or hep-
atic dysfunction, and documented terminal illness or cancer.
All subjects were administered medications according to
the current updated ACC/AHA/SCAI guidelines along with
standard rehabilitation programs for MI [27].
The study protocol conformed to the Declaration of
Helsinki and was approved by the ethics committee of
Navy General Hospital. All subjects signed written informed
consent for enrollment in the study and treatment. The
trial was monitored by an independent data and safety
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and as needed to assess adverse events.
Study design and treatment randomization
The eligible patients were assigned randomly to each of
two groups (WJMSCs or placebo control) in a 1:1 fashion
using a computer-generated randomization of sequence
numbers (Fig. 1). Physicians and other clinical personnel
remained blind to the treatment assignment throughout
the study. Day 0 was defined as the day of PCI. During
days 5–7, all subjects were assigned randomly into either
the WJMSC group, receiving 6 × 106 WJMSCs through
intracoronary infusion as described previously [28], or the
placebo group, with a placebo injected via the same deliv-
ery method as that of the WJMSC group. Safety was eval-
uated on days 0 and 3, as well as 1, 4, 12 and 18 months
post-treatment. Cardiac nuclear studies were performed
pre-treatment and at four months post-treatment. Two-
dimensional echocardiograms were measured before cell
transfer and 4, 12 and 18 months after cell transplantation
or placebo infusion.Fig. 1 Enrollment and outcomesStudy end points
The primary end point was safety: the incidence of ad-
verse events (AEs) within 18 months, including death,
nonfatal MI, stroke, hospitalization for worsening heart
function, severe arrhythmias, repeated coronary inter-
vention, stent thrombosis, coronary artery microvascular
obstruction, immune system disorders, or ectopic tissue
formation, was monitored and quantified. Laboratory as-
says, including biochemical assays, hematologic, tumor
and immune indexes and Holter monitoring, were per-
formed at the different follow-up times specified above.
The secondary end point was efficacy, which was
assessed in terms of the absolute change in myocardial
viability and perfusion in the infarcted region from the
baseline to 4 months post-treatment, as well as the global
LV ejection fraction (LVEF) from baseline to 18 months
post-treatment, as measured by F-18-fluorodeoxyglucose
positron emission computed tomography (F-18-FDG-
PET), 99mTc-sestamibi single-photon emission computed
tomography (99mTc-SPECT) and two-dimensional echo-
cardiogram (ECG), respectively.
Table 1 Baseline characteristics of the patients
Characteristic Placebo WJMSCs P value
(n = 58) (n = 58)
Risk factor
Age (years) 56.7±1.7 57.3±1.3 0.79
Men - number (%) 51(87.9) 55(94.8) 0.18
Body-mass index (kg/m2) 25.4±0.3 24.9±0.3 0.26
Diabetes mellitus - number (%) 14(24.1) 17(29.3) 0.52
Hyperlipidemia - number (%) 22(37.9) 21(36.2) 0.84
Hypertension - number (%) 26(44.8) 33(56.9) 0.19
Smoking (current of former) -number (%) 32(55.2) 34(58.6) 0.70
Family history of coronary heart disease - number (%) 20(34.5) 17(29.3) 0.55
Coronary artery disease - number (%) 0.19
1-Vessel disease 28(48.3) 21(36.2)
2-Vessel disease 16(27.6) 14(24.1)
3-Vessel disease 14(24.1) 23(39.7)
Infarct treatment
Infarct-related artery - number (%) 0.55
Left anterior descending artery 31(53.4) 29(50.0)
Left circumflex artery 6(10.3) 10(17.2)
Right coronary artery 21(36.2) 19(32.8)
PCI for additional stenoses in non-infarct-related vessels - number (%) 10(17.2) 15(25.9) 0.25
Time from symptom onset to first reperfusion therapy-hour
Mean 7.3±0.5 7.2±0.5 0.81
Median 6.3 7.3
Drug-eluting stent - number (%) 58(100) 58(100) 1
Gp II b/IIIa inhibitor during acute PCI - number (%) 7(12.1) 8(13.8) 0.78
Intravenous catecholamines - number (%) 3(5.2) 4(6.9) 0.69
Maximal creatine kinase (U/L) 1899±273 1653±206 0.93
Maximal creatine kinase MB (U/L) 192±21 170±17 0.42
Maximal troponin T (μg/L) 18.2±3.1 24.7±4.1 0.61
TIMI flow grade
Before PCI - number (%) 0.93
Grade 0 or 1 42(72.4) 42(72.4)
Grade 2 8(13.8) 7(12.1)
Grade 3 8(13.8) 9(15.5)
After PCI - number (%) 0.55
Grade 0 or 1 0(0) 0(0)
Grade 2 1(1.7) 2(3.4)
Grade 3 57(98.3) 56(96.6)
Baseline quantitative measure of LV function
Global left ventricular ejection fraction (%)
Mean 51.1±1.0 52.0±0.9 0.51
Left venticular fractional shortening (%)
Mean 26.4±0.6 27.2±0.6 0.33
Wall motion score index (17-segment model)
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Table 1 Baseline characteristics of the patients (Continued)
Mean 1.28±0.03 1.29±0.02 0.62
End-systolic volume (ml)
Mean 64.6±2.8 63.3±2.7 0.68
End-diastolic volume (ml)
Mean 129.9±3.5 130.4±3.6 0.90
Cell therapy
Time from reperfusion to infusion of study therapy-days
Mean 6.3±0.1 6.1±0.1 0.25
Median 6.5 6.0
TIMI flow grade before study therapy
Mean 2.98±0.02 2.97±0.02 0.56
Median 3 3
TIMI flow grade after study therapy
Mean 2.98±0.02 2.97±0.02 0.56
Median 3 3
Current medication - number (%)
Aspirin and clopidogrel 58(100) 58(100) 1
Beta-blocker 48(82.8) 42(72.4) 0.18
ACE-inhibitors or angiotensin-receptor B 43(74.1) 42(72.4) 0.83
Stains 54(93.1) 54(93.1) 1
Data are means (SE) or number (%) unless otherwise stated. TIMI trial grades are defined as follows: grade 0, no perfusion; grade 1, penetration without perfusion;
grade 2, partial perfusion; and grade 3, complete perfusion. ACE angiotensin-converting enzymes, LV left ventricular, PCI percutaneous coronary intervention
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The protocol of WJMSCs preparation was approved by
the General Logistics Department of the PLA and the
Navy General Hospital Ethical Review Board. Twenty-one
human umbilical cords were obtained, with the consent of
the parents, from healthy donors, who had no complica-
tions throughout the pregnancy, no history of disease, and
a full-term birth by caesarian section, and were aseptically
stored in sterile saline and processed within six hours
from partum to obtain the umbilical cord. After removal
of blood vessels, the abundant extracellular matrix of
Wharton’s jelly, which is a mucous tissue continuum from
the subamnion to the perivascular region, was scraped off
with a scalpel, finely cut and rinsed in sterile phosphate-
buffered saline. The WJMSCs were isolated by a non-
enzymatic method and cultured as described previously
[18]. The WJMSCs were purified in a central cell-
processing laboratory following the regulatory guidelines
of the International Conference on Harmonization and
the US Food and Drug Administration [29]. All proce-
dures were performed and all solutions were prepared
under Good Manufacturing Practice (GMP).
The infused WJMSCs were harvested at passage 3,
during which ≥95 % of cells expressed CD29, CD73,
CD90 and CD105, while the expression of CD45, CD34,
CD14, CD79 and HLA-DR was 2 % or less. Releasedcells were negative for the pathogenic microorganisms
HBV, HCV, HIV, cytomegalovirus, syphilis and exhibited
ALT and endotoxin levels within 40 IU/L and 0.5 EU/
mL, respectively. Final processing incorporated a total
cell count and cell viability (≥85 %) determination by
trypan blue testing. Based on the results from our ani-
mal experiments, we decided on a dose of 6 × 106
WJMSCs by intracoronary transplantation in this trial.
In brief, a dose-escalation study for intracoronary deliv-
ery of WJMSCs involved 12 pig models of AMI, weigh-
ing 28–35 kg, of mixed gender. The dose was escalated
at 1, 2, 3, 6 x 106 with a 30-minute interval. A coronary
angiogram as well as left ventriculogram was obtained at
15 minutes following each infusion. Blood flow to the
distal left anterior descending artery (LAD), measured
under fluoroscopy by counting the number of heart
beats required to fill this region of the vessel with con-
trast, was not changed at bolus doses up to 6 × 106
WJMSCs. Significant changes in LV wall motion were
revealed until administration of the 3 × 106 dose [30].
The placebo consisted of a vehicle (saline with 10,000 U/L
heparin) injected without cells.
The cells were shipped at 4 °C and delivered to each
catheterization laboratory at the 11 participating cardi-
ology centers, using a standard operating procedure.
After extensive discussion with the enrolled subjects,
Table 2 Clinical events during the 18 months follow-up period
Event Placebo WJMSCs P value
Events during procedure (n=58) (n=58)
Death 0 0
Obstruction of related-vessel 0 0
Severe arrhythmia 0 0
Events 6-mo follow-up (cumulative)a (n=57) (n=58)
Death 1 0 0.49b
Recurrence MI 0 0
Rehospitalization for heart failure 0 1 1.0b
Stent thrombosis 0 0
Revascularization 0 1 1.0b
Cerebral infarction 0 0
Arrhythmia 0 0
Immune system disorder
Ectopic tissue formation 0 1 1.0b
Combined events
Death or MI 1 0 0.49b
Death, recurrence of MI, revascularization procedure 1 1 1b
Death, MI, or rehospitalization for heart failure 1 1 1b
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia 1 1 1b
Immune system disorder, ectopic tissue formation 0 1 1b
Events 12-mo follow-up (cumulative)
Death 1 0 0.49b
Recurrence MI 0 0
Rehospitalization for heart failure 0 1 1.0b
Stent thrombosis 0 0
Revascularization 0 1 1.0b
Cerebral infarction 0 0
Arrhythmia 0 0
Immune system disorder 0 0
Ectopic tissue formation 1 1 1.0b
Combined events
Death or MI 1 0 0.49b
Death, recurrence of MI, revascularization procedure 1 1 1b
Death, MI, or rehospitalization for heart failure 1 1 1b
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia 1 1 1b
Immune system disorder, ectopic tissue formation 1 1 1b
Events 18-mo follow-up (cumulative)
Death 1 0 0.49b
Recurrence MI 0 0
Rehospitalization for heart failure 0 1 1.0b
Stent thrombosis 0 0
Revascularization 0 1 1.0b
Cerebral infarction 0 0
Arrhythmia 0 0
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Table 2 Clinical events during the 18 months follow-up period (Continued)
Immune system disorder 0 0
Ectopic tissue formation 1 1 1.0b
Combined events
Death or MI 1 0 0.49b
Death, recurrence of MI, revascularization procedure 1 1 1b
Death, MI, or rehospitalization for heart failure 1 1 1b
Death, MI, stroke, rehospitalization for heart failure, severe arrhythmia 1 1 1b
Immune system disorder, ectopic tissue formation 1 1 1b
a1 Patient was lost in the placebo group. bFisher’s exact test was used
MI myocardial infarction
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treatment. After arterial puncture and administration of
8 000 U heparin, 6 × 106 WJMSCs dispersed in 10 mL
heparinized saline (saline with 10,000 U/L heparin), or
the placebo, were infused using a stop-flow technique
through an over-the-wire balloon catheter positioned
within the stent segment as described previously [28].
Contrast medium was injected into the infarct-related
artery to ascertain vessel patency after cell infusion.
F-18-FDG-PET and 99mTc-sestamibi SPECT examination
F-18-FDG- PET (GE Millennum VG Hawkeye, Israel) and
99mTc-sestamibi SPECT (Varicam, GE-Elscint, Haifa,
Israel) was performed in patients at one day before and
four months after the procedure. After an overnight fast
for at least 12 hours, patients were given an oral glucose
load according to their serum glucose level. Sequential
measurements of serum glucose were made until the
serum glucose level reached 7.8 – 8.9 mmol/L and then
18F-FDG (222–296 MBq) and 99mTc-sestamibi (555–740
MBq) were injected intravenously, respectively. Myocar-
dial images were reconstructed using a standard filtered
back projection and displayed as a series of short-axis,
horizontal and vertical long-axis slices. Mean signal inten-
sities were measured in the respective areas supplied by
the three major coronary arteries in three-axis views. Re-
sults were calculated using F-18–FDG-PET and 99mTc-
sestamibi SPECT bull’s-eye views. All parameters were an-
alyzed independently by two experienced observers who
were unaware of the treatment assignment.
Two-dimensional echocardiogram examination
Patients who received cell grafts or standard treatment
underwent echocardiography consecutively 1–2 days be-
fore cell/placebo infusion and at 4, 12 and 18 months
follow-up. A 17-segment echocardiogram was performed
to measure regional left ventricular wall motion score,
end-systolic volume, end-diastolic volume and LVEF by
using standard methods of the American Society of
Echocardiography [31], and were analyzed independentlyby two experienced observers who were unaware of pa-
tients’ treatment assignments.
Statistical analyses
The population size of patient enrollment was influ-
enced by the difficulty in selecting eligible patients be-
cause the inclusion criteria used in our study selected
only those patients with AMI who had undergone pri-
mary PCI within 12 hours and who had also agreed to
accept a WJMSC intracoronary transplant five days after
their first PCI operation. Very few patients were deemed
eligible. To address this issue, we expanded the study to
include more hospitals. We also performed a statistical
analysis specifically to determine whether the study
population was normally distributed. To ascertain the ef-
ficacy, including PET and SPECT at month 4, and two
dimensional-ECG at months 4, 12 and 18, with variables
adjusted by baseline values, analysis of covariance
(ANCOVA) was performed to assess differences between
the placebo and WJMSC treatment groups. To estimate
the treatment effect, differences in least-squares means
and the corresponding 95 % confidence intervals (CI)
were calculated based on the ANCOVA model. The Wil-
coxon or Student’s t-test was used to compare changes
between the baseline and follow-up values according to
the distribution of variables. Categorical variables were
analyzed by chi-square or Fisher’s exact test, as appropri-
ate. Continuous variables were expressed as means ±
standard errors (SE) unless otherwise stated. Categorical
data were presented as frequencies and percentages. All
statistical tests were two-sided, and P <0.05 was consid-
ered statistically significant. All analyses were performed




A total of 160 subjects with ST-elevation AMI were
screened, and 116 eligible subjects signed written in-
formed consent to participate in the study. All patients
Table 3 Quantitative measures of blood index
Blood index Placebo WJMSCs P value
(number = 55) (number = 57)
CD3(%)
Baseline 66.8±0.9 67.6±0.8 0.48
3 Days 67.6±1.1 69.1±0.9 0.29
P value(baseline vs.3d) 0.43 0.08
1 Mo 67.3±1.0 66.6±0.9 0.53
P value (baseline vs.1 mo) 0.58 0.18
4 Mo 65.2±0.7 66.3±0.9 0.34
P value (baseline vs.6 mo) 0.06 0.11
12 Mo 66.2±0.9 66.4±0.8 0.81
P value (baseline vs.12 mo) 0.64 0.16
18 Mo 67.1±1.0 66.8±0.9 0.76
P value (baseline vs.18 mo) 0.66 0.29
CD4(%)
Baseline 39.6±1.2 40.1±0.8 0.70
3 Days 40.4±1.1 39.3±0.8 0.39
P value (baseline vs.3 d) 0.37 0.24
1 Mo 38.2±1.0 37.1±0.7 0.34
P value (baseline vs.1 mo) 0.09 <0.0001
4 Mo 37.7±1.1 38.0±0.8 0.75
P value (baseline vs.6 mo) 0.09 0.02
12 Mo 37.6±0.9 38.2±0.6 0.58
P value (baseline vs.12 mo) 0.11 0.03
18 Mo 38.8±1.1 39.2±0.9 0.45
P value (baseline vs.18 mo) 0.09 0.16
CD8(%)
Baseline 21.9±0.9 22.4±0.8 0.39
3 Days 21.3±0.8 22.9±0.8 0.13
P value (baseline vs.3 d) 0.36 0.16
1 Mo 21.5±0.5 22.8±0.7 0.14
P value (baseline vs.1 mo) 0.63 0.47
4 Mo 21.5±0.7 21.8±0.7 0.78
P value (baseline vs.6 mo) 0.66 0.32
12 Mo 23.2±0.4 22.2±0.6 0.16
P value (baseline vs.12 mo) 0.12 0.80
18 Mo 22.4±0.7 23.6±0.9 0.21
P value (baseline vs.18 mo) 0.56 0.71
IgG(g/L)
Baseline 11.1±0.3 10.7±0.3 0.42
3 Days 11.3±0.3 11.0±0.2 0.34
P value (baseline vs.3d) 0.41 0.39
1 Mo 11.5±0.4 10.9±0.4 0.13
P value (baseline vs.1 mo) 0.10 0.63
Table 3 Quantitative measures of blood index (Continued)
4 Mo 10.9±0.4 10.3±0.4 0.48
P value (baseline vs.6 mo) 0.74 0.36
12 Mo 11.8±0.3 11.3±0.4 0.31
P value (baseline vs.12 mo) 0.09 0.13
18 Mo 11.6±0.5 11.1±0.5 0.18
P value (baseline vs.18 mo) 0.11 0.64
IgM(g/L)
Baseline 1.10±0.10 1.07±0.08 0.80
3 Days 1.15±0.09 1.05±0.07 0.38
P value (baseline vs.3d) 0.24 0.67
1 Mo 1.24±0.11 1.23±0.10 0.69
P value (baseline vs.1 mo) 0.28 0.15
4 Mo 1.17±0.10 1.05±0.08 0.35
P value (baseline vs.6 mo) 0.50 0.69
12 Mo 1.14±0.06 1.15±0.05 0.55
P value (baseline vs.12 mo) 0.66 0.19
18 Mo 1.35±0.11 1.31±0.10 0.59
P value (baseline vs.18 mo) 0.39 0.24
CEA(ng/ml)
Baseline 2.21±0.14 2.63±0.17 0.08
3 Days 2.47±0.15 2.55±0.17 0.71
P value (baseline vs.3 d) 0.03 0.48
1 Mo 2.33±0.14 2.76±0.19 0.11
P value (baseline vs.1 mo) 0.33 0.40
4 Mo 2.37±0.15 2.42±0.15 0.91
P value (baseline vs.6 mo) 0.25 0.21
12 Mo 2.33±0.18 2.44±0.16 0.62
P value (baseline vs.12 mo) 0.58 0.34
18 Mo 2.22±0.16 2.55±0.24 0.16
P value (baseline vs.18 mo) 0.21 0.34
CRP(mg/L)
Baseline 5.72±0.53 6.47±0.49 0.27
3 Days 4.99±0.51 5.47±0.48 0.31
P value (baseline vs.3 d) 0.12 0.06
1 Mo 3.70±0.40 3.54±0.31 0.80
P value (baseline vs.1 mo) <0.0001 <0.0001
4 Mo 3.20±0.33 3.34±0.30 0.54
P value (baseline vs.6 mo) <0.0001 <0.0001
12 Mo 3.04±0.19 3.00±0.29 0.46
P value (baseline vs.12 mo) <0.0001 <0.0001
18 Mo 3.56±0.43 3.42±0.38 0.76
P value (baseline vs.18 mo) <0.0001 <0.0001
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ALT(U/L)
Baseline 30.5±1.8 32.8±2.1 0.41
3 Days 31.6±2.1 32.9±2.7 0.85
P value (baseline vs.3 d) 0.42 0.98
1 Mo 30.3±1.8 28.3±1.3 0.68
P value (baseline vs.1 mo) 0.96 0.47
4 Mo 29.3±1.1 29.9±1.2 0.72
P value (baseline vs.6 mo) 0.87 0.59
12 Mo 27.2±1.1 27.4±1.1 0.94
P value (baseline vs.12 mo) 0.36 0.31
18 Mo 29.2±1.4 28.1±1.2 0.61
P value (baseline vs.18 mo) 0.83 0.43
TBIL(μmol/L)
Baseline 16.7±1.5 15.1±1.3 0.63
3 Days 11.6±0.6 11.5±0.5 0.89
P value (baseline vs.3 d) 0.0003 0.006
1 Mo 15.1±0.7 13.8±0.6 0.32
P value (baseline vs.1 mo) 0.32 0.31
4 Mo 14.5±1.0 16.0±1.1 0.27
P value (baseline vs.6 mo) 0.22 0.60
12 Mo 14.2±0.7 15.6±0.5 0.12
P value (baseline vs.12 mo) 0.14 0.76
18 Mo 14.6±0.7 13.4±0.6 0.36
P value (baseline vs.18 mo) 0.31 0.28
BUN(mmol/L)
Baseline 5.30±0.18 5.63±0.22 0.28
3 Days 4.91±0.19 5.19±0.17 0.12
P value (baseline vs.3 d) 0.06 0.07
1 Mo 5.10±0.18 5.26±0.23 0.96
P value (baseline vs.1 mo) 0.36 0.22
4 Mo 5.29±0.17 5.21±0.18 0.47
P value (baseline vs.6 mo) 0.95 0.13
12 Mo 5.42±0.18 5.46±0.20 0.89
P value (baseline vs.12 mo) 0.68 0.57
18 Mo 5.22±0.23 5.33±0.32 0.85
P value (baseline vs.18 mo) 0.46 0.29
CRE(μmol/L)
Baseline 84.5±2.3 81.8±2.2 0.39
3 Days 81.2±2.0 77.9±2.1 0.26
P value (baseline vs.3 d) 0.14 0.14
1 Mo 78.5±2.4 76.3±2.0 0.46
P value (baseline vs.1 mo) 0.06 0.07
4 Mo 83.5±2.2 78.2±2.0 0.07
P value (baseline vs.6 mo) 0.71 0.17
Table 3 Quantitative measures of blood index (Continued)
12 Mo 84.0±2.0 80.4±1.8 0.19
P value (baseline vs.12 mo) 0.84 0.63
18 Mo 82.6±2.1 79.7±2.7 0.48
P value (baseline vs.18 mo) 0.56 0.61
Plus–minus values are means ± SE. P values of between-group comparisons
were determined by Student’s t-test or nonparametric Mann–Whitney U tests.
P values of within-group comparisons were determined by ANOVA with 95 %
CIs. ALT alanine aminotransferase, ANOVA analysis of variance, BUN blood urea
nitrogen, CEA carcino-embryonic antigen, CI confidence interval, CRP C reactive
protein, TBIL total bilirubin
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primary PCI (Table 1). After five days, they were
assigned evenly and randomly to the WJMSC or placebo
groups (Fig. 1). The baseline characteristics and clinical
interventions of reperfusion and medication were well-
matched in the two groups (Table 1). During the 18-
month follow-up period in the placebo group, one pa-
tient withdrew for missed follow-up due to a move, one
patient died 10 days after discharge and one patient
could not complete the follow-up at 12 months due to a
diagnosis of leukemia. In the WJMSC group, one subject
could not complete the four month follow-up due to a
diagnosis of advanced stomach cancer (Fig. 1). There-
fore, the findings from 58 patients in the WJMSC group
and 57 patients in the placebo group were analyzed sta-
tistically in this trial as shown in Fig. 1.
Adverse events (AEs)
The major adverse cardiac events (MACEs) and other
clinical AEs encountered are summarized in Table 2.
No major peri-procedural complications occurred in ei-
ther group. As mentioned above, one subject in the pla-
cebo group suffered sudden cardiac death 10 days after
discharge. In the WJMSC group, one subject was re-
hospitalized due to heart failure induced by a respiratory
infection two weeks post-treatment, and one subject
required re-vascularization for in-stent restenosis in
the infarct-related coronary artery four months post-
treatment. No new arrhythmias were recorded on the
Holter monitor study during the 18-month follow-up.
The groups did not differ in occurrences of MACEs,
including death, recurrences of AMIs and re-hospitalization
due to heart failure, during the course of treatment and the
18-month follow-up period.
In the WJMSC group, one patient was diagnosed with
advanced stomach cancer three months post-treatment.
However, no evidence of ectopic tissue formation and
no increase in the levels of tumor-associated antigens
were observed in the remaining subjects during the
follow-up. WJMSC infusion induced neither acute nor
persistent immune or biochemical abnormalities, as
shown in Table 3.
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No difference in the intensity of F-18-FDG-PET signals
was observed between the WJMSC and placebo group at
baseline. However, there was a significantly greater in-
crease in the tracer uptake within the infarcted area
from baseline to four months post-treatment in the
WJMSC group compared with the placebo group. As
shown in Fig. 2a, the absolute increase in the F-18-FDG-
PET signal intensity was markedly higher in the WJMSC
group (6.9 ± 0.6 %, 95 % CI 5.7−8.2) than in the placebo
group (3.3 ± 0.7 %, 95 % CI 1.8−4.7), (P<0.0001).
Myocardial perfusion
The 99mTc-SPECT imaging analysis of myocardial per-
fusion showed a similar total infarcted area at baseline
in both groups (Fig. 2b). An increase in myocardial per-
fusion was observed in both groups four months post-
treatment compared with baseline (Fig. 2b). However, as
shown in Fig. 2b, there was a significantly higher abso-
lute 99mTc-SPECT signal intensity in the WJMSC group
(7.1 ± 0.8 %, 95 % CI 5.4−8.8) compared with the pla-
cebo group (3.9 ± 0.6, 95 % CI 2.8−5.0), (P = 0.002).Fig. 2 a Mean F-18-FDG-PET signal intensity in the infarct vessel area meas
mean F-18-FDG-PET signal intensity changes and absolute changes betwee
ance (ANCOVA). T-bars show the standard errors. b Mean signal intensity o
before and four months after transplantation. Comparison of mean 99mTc-
WJMSC group and the placebo group by ANCOVA. T-bars show the standaLeft ventricular function
As shown in Fig. 3 and Table 4, patients treated with
WJMSCs experienced a 7.8 ± 0.9 (6.0 to approximately
9.7) LVEF increase over baseline at 18 months com-
pared with the 2.8 ± 1.2 (0.4 to approximately 5.1) in-
crease in the placebo group (p = 0.001). Concomitantly,
the absolute decreases in LV end-systolic volumes and
LV end-diastolic volumes at 18 months in the WJMSC
group were significantly greater than those in the pla-
cebo group (P = 0.0004, P = 0.004, respectively).
Discussion
In this randomized, double-blind, controlled trial, we
reported the safety and efficacy of intracoronary allo-
geneic WJMSC transplantation in patients with ST-
elevation AMI. A reduction in myocardial infarct size
and improved heart function were confirmed by the
myocardial viability and perfusion measurements, as
well as the global LVEF. Importantly, WJMSC trans-
plantation prevented post-infarct LV adverse remodel-
ing, as evidenced by the changes in the LVEDV and
LVESV at 18 months.ured before and four months after transplantation. Comparison of
n the WJMSC group and the placebo group using analysis of covari-
f 99mTc-MIBI perfusion imaging in the infarcted vessel area measured
MIBI signal intensity changes and absolute changes between the
rd errors WJMSC Wharton’s jelly-derived mesenchymal stem cells
Fig. 3 a Comparison of changes in the global left ventricular ejection fraction (LVEF) between the WJMSC group and the placebo group
measured by two dimensional-echocardiograph before transplantation and at the 4-, 12- and 18-month follow-ups. b. The absolute changes in
LVEF, LVESV and LVEDV between the WJMSC group and the placebo group at 18 months measured by ECG and analyzed by ANCOVA. T-bars
show the standard errors ANCOVA analysis of covariance, ECG echocardiogram, LVEDV left ventricular end-diastolic volume, LVESV left ventricular
end-systolic volume, WJMSC Wharton’s jelly-derived mesenchymal stem cells
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exists during which stem cell-based therapies can exert a
therapeutic effect [7]. Thus, stem cells that meet clinical
grade parameters in terms of purity, potency, identity,
and dose must be readily available. However, the desired
dose is difficult to obtain with autologous MSCs, be-
cause they cannot be expanded and processed in less
than 14 days [12, 13], thus reducing their usefulness due
to missing the optimal time window for cell treatment
after AMI. This study provides an exploratory roadmap
for the introduction of a promising and urgently needed
cellular therapy in clinical practice, based on the concur-
rent microenvironmental conditions and stage of the
disease. It promises an off-the-shelf product for AMI pa-
tients, backed by a solid procedure and a validated infra-
structure that can be administered to eligible patients
during the most favorable time window.
Notably, no signs of an immune response triggered by
the allogeneic WJMSC transplantation, ectopic tissue for-
mation or increased levels of tumor-associated antigenswere observed in this study. One patient in the WJMSC
group was diagnosed with advanced stomach cancer at
the three-month follow-up; however, the tumor-associated
antigen findings and pathological examination results in-
dicated that the tumor was not likely to have derived from
the WJMSCs. In addition, the intracoronary injection of
WJMSCs, unlike BMSCs which could be associated with
acute complications such as coronary occlusion during
transfer surgery [12], did not impair the TIMI flow grade
or trigger an increase in troponin concentrations, demon-
strating that no microvascular obstruction or coronary ar-
tery occlusion had occurred during or after the treatment
(Table 2). Taken together, the current results support the
conclusion that WJMSC transplantation is relatively safe
at least up to 18 months.
Based on previous studies and meta analyses [7–11],
there were slight but significant improvements (from 2.5
to 3.66 % of LVEF) in LV function and a significant de-
crease in the infarct size −4.03 % of patients with AMI
after autologous bone marrow stem cell therapy. Cardiac
Table 4 Quantitative measures of left ventricular function
Variable Placebo (95 % CI) WJMSCs(95 % CI) P value
(number = 55) (number = 57)
Global LVEF (%)
Baseline
Mean 51.0±1.1(48.8~53.3) 52.1±1.0(50.2~54.1) 0.46
4 Months
Mean 54.2±0.9(52.5~56.1) 58.5±0.7(57.1~60.0) 0.0003
Difference 3.2±0.9(1.4~5.0) 6.4±0.7(4.9~7.9) 0.008
P value (baseline vs.6 months) 0.0009 <0.0001
12 Months
Mean 54.5±0.8(52.8~56.2) 58.8±0.8(57.3~60.4) 0.0002
Difference 3.5±0.8(1.9~5.0) 6.7±0.8(5.1~8.3) 0.004
P value (baseline vs.12 months) <0.0001 <0.0001
18 Months
Mean 54.0±0.8( 52.3~55.7) 60.0±0.5 (58.9~61.0) <0.0001
Difference 2.8±1.2(0.4~5.1) 7.8±0.9(6.0~9.7) 0.001
P value (baseline vs.18 months) 0.05 <0.0001
LVFS (%)
Baseline
Mean 26.6±0.7(25.2~27.9) 27.3±0.6(26.0~28.6) 0.42
4 Months
Mean 29.7±0.7(28.3~31.0) 32.6±0.6(31.4~33.9) 0.002
Difference 3.1±0.6(1.9~4.3) 5.3±0.6(4.0~6.6) 0.01
P value (baseline vs.6 months) <0.0001 <0.0001
12 Months
Mean 29.8±0.6(28.5~31.0) 32.7±0.5(31.7~33.8) 0.0005
Difference 3.2±0.5(2.1~4.3) 5.4±0.5(4.3~6.5) 0.005
P value (baseline vs.12 months) <0.0001 <0.0001
18 Months
Mean 28.6±0.6(20.8~35.6) 33.6±0.5(27.3~39.1) <0.0001
Difference 2.1±0.8(−8.9~13.5) 6.2±0.7(−4.1~16.4) <0.0001
P value (baseline vs.18 months) 0.01 <0.0001
WMSI (17-segment model)
Baseline
Mean 1.28±0.03(1.23~1.34) 1.29±0.03(1.24~1.34) 0.76
4 Months
Mean 1.16±0.02(1.11~1.21) 1.10±0.01(1.07~1.12) 0.02
Difference −0.12±0.02(−0.16~−0.09) −0.19±0.02(−0.23~−0.16) 0.003
P value (baseline vs.6 months) <0.0001 <0.0001
12 Months
Mean 1.15±0.02(1.11~1.20) 1.09±0.02(1.06~1.12) 0.02
Difference −0.13±0.02( −0.17~−0.10) −0.20±0.02(−0.23~−0.17) 0.003
P value (baseline vs.12 months) <0.0001 <0.0001
18 Months
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Table 4 Quantitative measures of left ventricular function (Continued)
Mean 1.16±0.9(1.02~1.40) 1.07±0.01(1.00~1.17) <0.0001
Difference −0.13±0.02(−0.42~0.08) −0.22±0.02(−0.57~0.04) 0.01
P value (baseline vs.18 months) <0.0001 <0.0001
End-systolic volume (ml)
Baseline
Mean 66.0±3.1(59.8~72.2) 63.1±2.8(57.5~68.7) 0.38
4 Months
Mean 63.4±2.8(57.7~69.0) 55.9±2.1(51.7~60.2) 0.07
Difference −2.6±1.8(−6.4~1.1) −7.2±1.9(−10.9~−3.5) 0.09
P value (baseline vs.6 months) 0.16 0.0003
12 Months
Mean 62.5±2.8(56.9~68.0) 55.1±2.1(50.9~59.4) 0.06
Difference −3.5±1.9(−7.3~0.2) −8.0±2.0(−12.1~−3.9) 0.12
P value (baseline vs.12 months) 0.11 0.0002
18 Months
Mean 62.8±0.9(59.1~66.6) 49.2±1.0(47.1~51.2) <0.0001
Difference −2. 9±2.1(−7.1~1.3) −14.0±2.2(−18.4~−9.5) 0.0004
P value (baseline vs.18 months) 0.2 <0.0001
End-diastolic volume (ml)
Baseline
Mean 132.2±3.9(124.3~140.0) 130.3±3.8(122.7~137.9) 0.49
4 Months
Mean 136.0±4.0(127.9~144.0) 133.2±3.2(126.8~139.5) 0.72
Difference 3.8±2.3(−0.7~8.4) 2.9±2.6(−2.3~8.0) 0.78
P value (baseline vs.6 months) 0.20 0.07
12 Months
Mean 134.5±3.9(126.6~142.4) 131.9±3.1(125.8~138.1) 0.60
Difference 2.4±2.5(−2.6~7.3) 1.6±2.8(−4.0~7.2) 0.84
P value (baseline vs.12 months) 0.45 0.22
18 Months
Mean 136.4±3.1(130.1~142.7) 122.7±1.6 (119.5~125.8) 0.0001
Difference 4.1±2.4(−0.8~9.0) −7.6±3.13(−13.9~−1.4) 0.004
P value (baseline vs.18 months) 0.1 <0.0001
LVEF, LVESV and LVEDV by two dimensional-ECG from baseline to 18 months post-treatment between the WJMSC group and placebo-control group were ana-
lyzed by ANCOVA. Treatment effects are expressed as differences in least-squares means (ANCOVA model) with 95 % CI ANCOVA analysis of covariance, CI confi-
dence interval, ECG echocardiogram, LVEDV left ventricular end-diastolic volume, LVESF left ventricular end-systolic volume, WJMSC Wharton’s jelly-derived
mesenchymal stem cells
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cardiomyocytes. Here, we verified that the transplanted
WJMSCs significantly increased myocardial viability
within the infarcted area as measured by F-18-FDG-PET,
which is considered sensitive and specific for assessing
viable myocardium [32, 33]. Concomitantly, the myocar-
dial perfusion in the infarcted area and the LVEF were
increased significantly after WJMSC transplantation.
Notably, even though the infarct size (−6.9 %) was notreduced greatly after the transfer of the WJMSCs, the
gradual improvements in LVEDV and LVESV over 18
months in the WJMSC group demonstrated that these
cells could prevent adverse LV remodeling effectively.
Previous studies have shown that the transfer of BMMCs
had no significant impact on LVEDV, suggesting that
BMMCs may have a limited effect on LV remodeling after
AMI [7, 8]. Taken together, our findings indicate that com-
bined optimal reperfusion therapy (stent implantation) and
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mal time frame can decrease the infarct size, enhance the
recovery of global and regional LV function and prevent
LV remodeling after AMI.
Our study was not designed to assess the underlying
mechanisms of WJMSC treatment that promote func-
tional recovery after AMI. Nevertheless, evidence supports
the idea that WJMSCs constitute a unique cell family with
a high degree of stemness and unique transcriptional pro-
files [34, 35]. We previously reported higher expression
levels of mesoderm and specialized cardiac progenitor cell
genes, including Brachyury (T), mesoderm posterior 1,
Flk-1, Nkx2.5 and Isl-1, which represent key transcription
factors of cardiac development [18]. These key character-
istics of WJMSCs indicate their strong potential to differ-
entiate into cardiomyocytes, endothelia, and to form
neovascular networks, to integrate into ischemic cardiac
tissues, all of which result in the improvement of heart
function [18–22]. Moreover, WJMSCs can secrete large
amounts of anti-apoptotic, angiogenic factors and growth
factors, exerting paracrine effects for the regeneration of
myocardium and coronary vessels [36].
Tumorigenesis is a major concern in the clinical appli-
cation of human ESCs and induced pluripotent stem
cells (iPS). Studies have demonstrated that normal kar-
yotypes were observed in WJMSCs harvested from pri-
mary, early and late passages, and teratomas were not
induced after WJMSC injection into severe combined
immune deficient (SCID) mice [37]. No ectopic tissues
or increased levels of tumor-associated antigens were
observed after WJMSC transplantation in this trial. Fur-
thermore, WJMSCs can regulate immunity by modulat-
ing the behavior of natural killer (NK) cells and T-cell
populations to evade immune responses and are well-
tolerated in allogeneic transplantation [24, 26].
In this study, a relatively lower dose of WJMSCs was
administered for intracoronary infusion because in our
previous clinical trial one patient suffered from a serious
complication of coronary artery occlusion during the
BMSC injection procedure [12]. However, the wide
safety margin found in the present study indicated that
higher doses of WJMSCs would be safe for clinical trials
in the future.
There is a limitation to this proof-of-concept study.
Although we used an especially important tool, PET, for
interpreting myocardial viability and predicting improve-
ments in cardiac function, contrast-enhanced magnetic
resonance imaging (CE-MRI) was not available in all
centers to assess cardiac function. This may be a draw-
back compared to recently related publications.
Conclusions
We demonstrated for the first time that intracoronary
delivery of prepared clinical-grade WJMSCs, a true stemcell population with highly expressing early cardiac tran-
scription factors, was safe in treating patients with an
AMI attack and could significantly improve myocardial
viability and heart function. Our original study provides
an exploratory roadmap to translate the promising cellu-
lar therapy into clinical practice according to the ur-
gency for treatment, the concurrent microenvironmental
conditions and the stage of disease. Therefore, this study
encourages additional clinical trials to determine
whether WJMSCs may serve as a novel allogeneic source
for cardiac stem cell-based therapies.
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